Shanghai Heartcare IPO: DCF Offers Decent Upside but Mind the Ongoing Lawsuit with Medtronic

300 Views12 Aug 2021 13:56
Our DCF valuation offers a price per share of HK$182.78 which is 6.9% higher than the upper end of the company’s indicative IPO price range of HK$160-171 per share.
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
(Paid Plans Only)
Top Quartile
Shifara Samsudeen, ACMA, CGMA
Equity Analyst
LightStream Research
JapanIndustrialsEquity Bottom-UpEquity Capital Markets